EVM
IMGN

Eaton Vance Management’s Immunogen Inc IMGN Stock Holding History

Eaton Vance Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-775
Closed -$6K – 3076
2021
Q1 		$6K Buy
+775
New +$6.33K ﹤0.01% 2555

Other funds holding IMGN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Eaton Vance Management's IMGN Position: Q2 2021 in Review

Eaton Vance Management sold out of Immunogen Inc (IMGN) in Q2 2021, closing a stake of 775 shares — an estimated $6K sold.

Eaton Vance Management first reported a position in IMGN in Q1 2021 and held it in 1 quarter. The position peaked at $6K in Q1 2021. 214 funds tracked by Wall St. Rank hold IMGN as of Q2 2021.

  • Eaton Vance Management reported no remaining Immunogen Inc position as of Q2 2021 after selling out during the quarter.
  • Eaton Vance Management sold 775 Immunogen Inc shares in Q2 2021, an estimated $6K.
  • Eaton Vance Management first reported a position in Immunogen Inc in Q1 2021 and held it in 1 quarter.
  • Eaton Vance Management's Immunogen Inc position peaked at $6K in Q1 2021.
  • 214 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2021.

Based on Eaton Vance Management's 13F filing for Q2 2021, filed 16 Aug 2021.